MedTrace Logo

Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis

NCT00185510 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2023-06-09

No results posted yet for this study

Summary

Purpose of the study:

One bothering feature of atopic dermatitis is its relapsing nature. Hence, it is worthwhile to test modes how to efficiently prevent relapses or at least increase the time until the disease recurs. In order to give recommendations to other patients, this study is to scientifically describe efficacy and safety of a given regimen, namely a maintenance therapy with two days a week Advantan.

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

Methylprednisolone Aceponate (Advantan, BAY86-4862)

In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.

DRUG

Placebo

2 days a week Vehicle (Advabase)

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-05-31
Completion
2006-06-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185510 on ClinicalTrials.gov